Creative Medical Tech Holdings, Inc. (CELZ) is experiencing an 81% surge in shares on Thursday following the company's announcement of FDA approval for expanded access therapy utilizing CELZ-201, also referred to as ImmCelz.
This cell-based program aims to manage abnormal glucose tolerance and prevent Type 1 Diabetes Mellitus in high-risk individuals.
The FDA granted an Orphan Drug Designation for CELZ-201 the day before.
CELZ is trading on the Nasdaq at $8.64, up 81.51% or $3.88 per share. It has traded between $3.93 and $13.30 in the past 52-week period.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.